
JOIN US
Liquid Biopsy in Advanced
Prostate Cancer: Stay Up to Date
When a liquid biopsy report identifies a targetable driver, treatment decisions are clear. When there is no driver identified, the next steps are more uncertain. Expert speakers will present their perspectives on liquid biopsy for treatment selection in prostate cancer and discuss emerging biomarker ctDNA tumor fraction reported on Foundation Medicine’s liquid biopsy test.
August 20, 2024
12:30 pm

BRANDON A. MAHAL, MD
Internationally Recognized Expert
in Prostate Cancer

TAKARA SCOTT
Lead, Medical Science Liaison
Foundation Medicine

JENNIFER MILLS, PhD
Moderator
Vice President, Medical Affairs,
Foundation Medicine